Asset profile

Ibalizumab · Trogarzo

Monoclonal antibody

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Approvedregulatory verdict

How the evidence outlook works ↗

Competitive landscape

60 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 59 same-indication.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ibalizumab (Trogarzo): this drugApprovedMonoclonal antibodyCD4 receptor
SemzuvolimabPhase 3Monoclonal antibodyCD4 receptor
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integrase
Cabotegravir (Vocabria / Cabenuva / Apretude)ApprovedSmall moleculeHIV integrase
Crofelemer (Mytesi)ApprovedSmall moleculeChloride channel (intestinal epithelium)
Darunavir (Prezista)ApprovedSmall moleculeHIV protease
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integrase
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptase
Elsulfavirine (Elpida)ApprovedSmall moleculeHIV reverse transcriptase
Elvitegravir (Stribild / Genvoya (component))ApprovedSmall moleculeHIV integrase
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptase
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptase
Fosamprenavir (Lexiva / Telzir)ApprovedSmall moleculeHIV protease
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120
Lenacapavir (Sunlenca / Yeztugo)ApprovedSmall moleculeHIV capsid
Maraviroc (Selzentry / Celsentri)ApprovedSmall moleculeCCR5 co-receptor

…and 45 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Compare head-to-head

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2028 (1)
December 2028 (1)
Phase 1HIVNot yet recruiting
Est. primary completion 2028-12-31 · NCT07635992 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.